ArnonSSDamusKThompsonBMiduraTFChinJ. Protective role of human milk against sudden death from infant botulism. J Pediatr. 1982;100(4):568-573. doi:10.1016/s0022-3476(82)80754-3.
2.
Centers for Disease Control and Prevention (CDC). Botulism Annual Summary, 2017. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. Accessed July 14, 2022. https://www.cdc.gov/botulism/surv/2017/index.html.
SobelJRaoAK. Making the best of the evidence: toward national clinical guidelines for botulism. Clin Infect Dis. 2017;66(suppl 1):S1-S3. doi:10.1093/cid/cix829.
5.
Division of Communicable Disease Control, California Department of Public Health. Infant Botulism Treatment and Prevention Program. Accessed July 14, 2022. http://www.infantbotulism.org/.
6.
FerreiraEGYatsudaFPiniM, et al. Implications of the presence of yeasts in tracheobronchial secretions of critically ill intubated patients. EXCLI J. 2019;18:801-811. doi:10.17179/excli2019-1631.
7.
PodschunRUllmannU. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589-603. doi:10.1128/CMR.11.4.589.
8.
ArnonSS. Creation and development of the public service orphan drug human botulism immune globulin. Pediatrics. 2007;119(4):785-789. doi:10.1542/peds.2006-0646.
ArnonSSSchechterRMaslankaSEJewellNPHathewayCL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354(5):462-471. doi:10.1056/NEJMoa051926.
12.
PayneJRKhouriJMJewellNPArnonSS. Efficacy of human botulism immune globulin for the treatment of infant botulism: the first 12 years post licensure. J Pediatr. 2018;193:172-177. doi:10.1016/j.jpeds.2017.10.035.